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RESEARCH
Factors that influence enrollment in syringe 
services programs in rural areas: a qualitative 
study among program clients in Appalachian 
Kentucky
Umedjon Ibragimov1* , Katherine E. Cooper1, Evan Batty2, April M. Ballard1, Monica Fadanelli1, Skylar B. Gross1, 
Emma M. Klein1, Scott Lockard3, April M. Young2 and Hannah L. F. Cooper1 
Abstract 
Background: Enrolling sufficient number of people who inject drugs (PWID) into syringe services programs (SSP) is 
important to curtail outbreaks of drug-related harms. Still, little is known about barriers and facilitators to SSP enroll-
ment in rural areas with no history of such programs. This study’s purpose was to develop a grounded theory of the 
role of the risk environment and individual characteristics of PWID in shaping SSP enrollment in rural Kentucky.
Methods: We conducted one-on-one semi-structured interviews with 41 clients of 5 SSPs that were established 
in rural counties in Appalachian Kentucky in 2017–2018. Interviews covered PWID needs, the process of becom-
ing aware of SSPs, and barriers and facilitators to SSP enrollment. Applying constructivist grounded theory methods 
and guided by the Intersectional Risk Environment Framework (IREF), we applied open, axial and selective coding to 
develop the grounded theory.
Results: Stigma, a feature of IREF’s meso-level social domain, is the main factor hampering SSP enrollment. PWID hes-
itated to visit SSPs because of internalized stigma and because of anticipated stigma from police, friends, family and 
healthcare providers. Fear of stigma was often mitigated or amplified by a constellation of meso-level environmental 
factors related to healthcare (e.g., SSPs) and social (PWID networks) domains and by PWID’s individual characteristics. 
SSPs mitigated stigma as a barrier to enrollment by providing low threshold services in a friendly atmosphere, and by 
offering their clients program IDs to protect them from paraphernalia charges. SSP clients spread positive information 
about the program within PWID networks and helped their hesitant peers to enroll by accompanying them to SSPs. 
Individual characteristics, including child custody, employment or high social status, made certain PWID more suscep-
tible to drug-related stigma and hence more likely to delay SSP enrollment.
Conclusions: Features of the social and healthcare environments operating at the meso-level, as well as PWID’s indi-
vidual characteristics, appear to enhance or mitigate the effect of stigma as a barrier to SSP enrollment. SSPs opening 
in locations with high stigma against PWID need to ensure low threshold and friendly services, protect their clients 
from police and mobilize PWID networks to promote enrollment.
Keywords: Syringe services programs, People who inject drugs, Rural Appalachia, Stigma
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Introduction
Syringe services programs (SSPs) are a proven [1] and 
highly cost-effective [2–5] intervention to reduce the 
risk of HIV and hepatitis C virus (HCV) transmission 
among people who inject drugs (PWID). Modeling 
suggests that expanding SSPs as HIV prevention inter-
ventions in the United States (USA) would cost about 
$25,000 per quality-adjusted life-year [QALY] gained, 
significantly below $50,000 per QALY benchmark of 
public health cost-effectiveness [6]. As for HCV pre-
vention, SSPs may save about $364,000 per case averted 
[4]. Cost-savings of expanding SSP in combination with 
other evidence-based interventions may be particularly 
high for rural areas that have high prevalence’s of HCV 
and other drug-related harms [5].
Historically, SSPs have been scarce in the rural US 
though. In 2013, only 30 SSPs operated in rural areas, 
and their capacity and funding were lower than SSPs 
located in urban areas [7]. However, in response to the 
escalating epidemics of substance use disorder (SUD) 
and injection drug use (IDU)-related harms, includ-
ing HCV, the state of Kentucky established more than 
70 SSPs in five years following the legalization of this 
intervention in 2015 [8]. Almost half (n = 32) of these 
programs were opened in rural counties that were iden-
tified as experiencing or at high risk for IDU-related 
HIV and HCV outbreaks [9]. This unprecedented 
expansion of SSPs made Kentucky a US leader in the 
number of SSPs serving PWID in rural areas.
Despite rapid expansion, SSPs in rural areas may 
face challenges with PWID enrollment, which may 
hamper programs’ ability to address the epidemics of 
bloodborne infections at the population level. Lan-
caster et  al. found that only 49% of PWID sampled in 
five Appalachian Kentucky counties had ever utilized 
SSPs, although 80% of the study participants had been 
recruited in three counties where SSPs were operating 
[10]. Allen et al. reported that almost 30% of PWID in 
a rural West Virginia County received sterile syringes 
from sources other than SSP [11]. To prevent or cur-
tail outbreaks, a high proportion of PWID need to 
enroll and start using SSPs and other evidence-based 
programs. Modeling suggests that substantive and 
cost-effective reductions in HIV among PWID may be 
achieved if at least half of PWID population regularly 
receive SSP services [2]. Further, while SSPs may reach 
PWID indirectly via satellite and secondary exchange, 
in-person visits of PWID to SSPs are essential to link 
them to a comprehensive range of services, includ-
ing HIV and HCV testing and treatment, as well as 
SUD treatment, wound care, housing and other social 
services [12–16]. However, literature on factors that 
may influence PWID enrollment into SSP services in 
high-stigma areas with no history of harm reduction 
programs is limited.
In this regard, an important question in studying SSP 
expansion in areas with no history of such programs is 
assessing factors that may accelerate or slow down enroll-
ment into this program. Stigma is one such formidable 
barrier for PWID. It may take various forms, including 
public stigma (defined as negative stereotypes and judg-
mental attitudes toward PWID), enacted stigma (defined 
as overt ostracism and discrimination against PWID); 
anticipated stigma (defined as avoiding situations such as 
a visit to SSP that may disclose one’s drug use and expose 
one to enacted stigma); internalized stigma (defined 
as feelings of shame and unworthiness that affect one’s 
behaviors); and structural stigma (e.g., repressive drug 
policies and policing practices) [17–19]. Each of these 
forms of stigma either directly prevents PWID from 
engaging with SSPs and other health-related services, or 
fuels other forms of stigma and discrimination [10, 18–
27]. Stigma may differentially impact sub-populations of 
PWID—for example, women who inject drugs may be 
subject to stronger stigma than men [28]. Stigma is an 
important barrier to services in rural Appalachia: PWID 
living in this region report that anticipated stigma is a 
reason to avoid attending SSPs or obtaining and carrying 
clean syringes [10, 20, 26]. Public stigma against PWID 
and related local opposition to harm reduction hampered 
access to drug-related services in the region, including 
preventing new SSPs from opening or closure of existing 
ones [21, 24, 25, 29–33].
Given the importance of enrolling a high proportion of 
PWID into SSP in high-risk settings and limited knowl-
edge on barriers and facilitators of SSP enrollment in 
rural areas, we conducted a qualitative study among pro-
gram clients in five rural counties in Appalachian Ken-
tucky that had opened an SSP in 2017–2018. The study’s 
purpose was to develop a grounded theory of the role of 
the risk environment and individual characteristics in 
SSP enrollment among PWID. Since IDU-related stigma 
is prevalent in rural Kentucky, [10, 24, 29] we were espe-
cially interested in studying factors that may amplify or 
mitigate the role of stigma as a barrier to enrollment. The 
study findings may inform planning and implementation 
of SSP in rural areas.
Theoretical framework
We explore this topic using grounded theory methods—
a method of systematic exploration of raw data to infer 
major constructs and relationships among them to 
develop a theory explaining the phenomena of interest. 
While grounded theory originally prescribed the use of 
abductive logic without relying on a priori theories, con-
structivist grounded theory accompanies abductive logic 
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with sensitizing concepts. These sensitizing concepts 
may include theories and frameworks from the litera-
ture to inform the development of the grounded theory 
[34]. Following the advice by Charmaz on sensitizing 
concepts, we used frameworks as “…points of departure 
from which to study the data” [34 p. 259], not as defin-
ing premises of our grounded theory. This helped us to 
align our analysis and grounded theory with the existing 
literature on drug-related risks and services. Specifically, 
Collins and colleagues’ Intersectional Risk Environment 
Framework (IREF), [35] an extension of Rhodes’ Risk 
Environment Framework (REF) informed our analy-
ses. REF posits that drug-related risk behaviors, includ-
ing service utilization, are the function of influence and 
interaction of external forces mapped by REF into envi-
ronment domains (physical, social, policy, economical, 
law enforcement and healthcare) and levels (macro-, 
micro-, and, in some literature, meso-level). REF posits 
that stigma is a feature of macro-level social environ-
ment, rooted in negative stereotypes, norms and beliefs 
prevailing in rural communities, and intertwined with 
policy and law enforcement (“War on Drugs”) environ-
ments [29]. IREF extends REF by conceptualizing an 
intersecting social location of an individual (a set of indi-
vidual characteristics, such as age, gender, race, defined 
by the systems of oppression or privilege) as a mecha-
nism mediating and modifying the impact of risk envi-
ronment on individual health outcomes [35].
Methods
Study design
We employed a qualitative multiple-case study design; 
individual SSPs in each of the five study counties were 
treated as separate cases [36]. To preserve anonymity 
of the study participants, we do not mention the county 
names. A case study design is suitable for studying real-
world phenomenon (here, SSPs) in  situations where the 
boundaries between the phenomenon and the context 
(PWID networks, service providers, communities) are 
not clearly delineated. In multiple-case studies, each 
case (SSP) is considered a replication of an “experiment” 
generating data to develop and iteratively refine a theory 
explaining the phenomenon [36–38]. Prior to conducting 
interviews with SSP clients, we reviewed the interview 
guides with SSP managers, staff and directors of health 
districts overseeing local health departments in the study 
counties.
Setting
The study gathered data from SSPs in five counties in 
Appalachian Kentucky. These SSPs were managed by 
county health departments and located within county 
health centers; no mobile SSPs had been launched in 
these counties at the time of data collection. Service 
provision was not uniform across the SSPs: some were 
open during most business hours four or five days a 
week, while others were open only a couple of hours 
one or two days a week. Some SSPs had more strict 
syringe exchange policies than others (e.g., at some 
SSPs clients could exchange up to 200 syringes per visit, 
while in others a cap was set at 20 or 40). All counties 
were rural, ranking between 7 and 9 on USDA Rural–
Urban Continuum Code (1—most urban, 9—most 
rural) and with population density ranging between 
23 and 85 people per sq. mile [39, 40]. As elsewhere 
in rural Appalachia, these counties struggle with high 
levels of health disparities, poverty and unemployment 
as the result of decline in coal mining and agriculture 
[40–43]. As in many US rural areas, these counties were 
geographically remote and residents were often iso-
lated; public transportation was limited and healthcare 
facilities operated under resource constraints [41, 42, 
44, 45]. The opioid epidemic that hit the area hard has 
been accompanied by a high prevalence of HCV, IDU, 
overdoses and condomless sex [46–50]. Four of the five 
study counties were determined by CDC to be experi-
encing or at high risk for HIV and HCV outbreaks due 
to IDU, with three of the counties ranking among the 
top 30 most vulnerable to such outbreaks [9]. Previous 
studies reported dense and overlapping social and drug 
use networks, often including members of the same 
families, as a key characteristic of the risk environment 
[51–53]. These dense social networks and intergenera-
tional ties are the main feature of communal resilience, 
defined as an ability of individuals, families and com-
munities to harness their social support systems to 
overcome or cope with multiple challenges of everyday 
life in these impoverished and underserved rural areas 
[51–53].
Sampling and recruitment
SSP clients were the population of interest for this 
study. Eligibility criteria included being aged 18 or 
older; receiving syringes at one of the five SSPs at least 
three times in the past three months; and residing in 
the county where SSP operated for at least six months. 
SSP clients were recruited in three ways: (1) via SSP 
staff, who referred interested clients to research assis-
tants (RAs); (2) RAs approached SSP participants at 
SSP premises; and (3) RAs contacted participants of the 
parent study cohort who reported using SSP services at 
the time of the survey and had agreed to be contacted 
about future research. Our final sample comprised of 
41 PWID—program clients. All participants provided 
verbal informed consent.
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Data collection
We collected data via in-person one-on-one semi-struc-
tured interviews. The interview guide covered the fol-
lowing topics: injection practices prior to attending the 
SSP and unmet needs; the processes of becoming aware 
of SSPs in the county and making the decision to start 
participating in it; and barriers and facilitators to the 
first SSP visit. Interviews were audiotaped with partici-
pant consent. In addition, we conducted a mini-survey 
to collect data on participants’ sociodemographic char-
acteristics, drug use and SSP service utilization patterns. 
Participants were offered $20 cash as a compensation for 
their time. Interviews were conducted between Decem-
ber 2018 and January 2020 (all SSPs had been operating 
for more than one year by the start of the interviews). 
The study has been approved by Emory University Insti-
tutional Review Board (protocol IRB00107426).
Data analysis
A constructivist grounded theory approach was used 
throughout the data collection and analysis phases [34]. 
Interview guides were iteratively reviewed and revised 
based on the study findings and emerging grounded 
theory. Interview records were transcribed verbatim and 
coded in NVivo 12.0 software (QSR International).
We started with a within-case analysis, in which we 
analyzed data from each county (there was one SSP in 
each county), one at a time. The within-case analysis 
had three stages—open, axial and selective coding—and 
each stage employed constant contrast and comparison 
techniques. We documented our analyses in memos for 
each county. After reading each transcript multiple times 
to immerse ourselves in the data, two coders started the 
open coding process independently by labeling concepts 
in four initial transcripts and developing the codebook. 
Concepts with similar meaning or pertaining to the same 
phenomena were combined into higher order catego-
ries. We revised the codebook iteratively as new codes 
and categories emerged while coding the remaining 
transcripts. Subsequently, every fourth transcript was 
double-coded to enhance reliability; discrepancies were 
resolved by having a third person code the discrepant 
text and subsequent discussion in the team. At the axial 
coding stage, we linked categories to each other by devel-
oping relational statements. During selective coding, we 
selected the central category (here, “stigma as a barrier to 
SSP”) most saliently related to our research question. We 
consulted our theoretical framework (the Intersectional 
Risk Environment Framework) when we labeled the 
major categories of the theory. For example, we grouped 
into IREF domains (e.g., policy, social, healthcare and law 
enforcement) the external factors related to the central 
category. This three-stage process was repeated for each 
county.
In the cross-case analysis stage, we refined the emerg-
ing grounded theory by comparing and contrasting major 
categories and the relationships between them across the 
counties (cases). Specifically, we looked for literal repli-
cations (similar findings) and theoretical replications 
(contrasting findings predicted by the theory) of the core 
categories and the relationships between them. This con-
trast and comparison process was recorded in the final 
memo, which encompassed findings from all counties 
and described the grounded theory reflecting differences 
and similarities across the counties.
Results
The study participants—SSP clients
Mini-surveys were completed by 37 out of 41 partici-
pants (four participants did not complete the mini-
survey; Table  1). Our full sample consisted of 18 men 
and 23 women (according to the screening data). The 
Table 1 Demographic characteristics, drug use practices and 
length of SSP participation (N = 37)
* % are calculated for participants who participated in the mini-survey (n = 37)
Characteristic n (%)*





White non-Hispanic 35 (94.6)
Other 1 (2.7)
Refused to answer 1 (2.7)
Commonly reported drugs used (past 3 months)
Methamphetamine 25 (67.6)
Marijuana 19 (51.3)
Prescription opioid painkillers 15 (40.5)




Fentanyl or Carfentanyl 6 (16.2)
Cocaine 5 (13.5)
Commonly reported drugs injected (past 3 months)
Methamphetamine 24 (64.9)
Prescription opioid painkillers 16 (43.2)
Heroin 12 (32.4)
Suboxone 11 (29.7)
Fentanyl or similar 5 (13.5)
Cocaine 3 (8.1)
Number of months since first visit to the SSP (mean, SD) 13.2 (7.8)
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subsample that responded to the mini-survey included 
17 women (45.9% [unless indicated otherwise, the 
denominator for percentages in this paragraph is 37—
the number of the mini-survey participants]) and 20 
men (54.1%), both young and middle-age adults, with 
mean age of 38 years. Almost all participants self-iden-
tified as non-Hispanic white, consistent with the local 
racial/ethnic composition. The most commonly used 
drugs were methamphetamines (67.6%), marijuana 
(51.3%), prescription opioids (40.5%) and prescrip-
tion sedatives (40.5%). Methamphetamines were also 
the most commonly injected drug in the three months 
prior to the interview (64.9%), followed by prescrip-
tion opioids (43.2%) and heroin (32.4%). On average, 
participants started visiting study SSPs more than a 
year before the interview time (mean = 13.2  months). 
According to the individual interview data, about half 
of our participants reported postponing their first visit 
to SSP for a month or longer after first hearing about 
the program, and several of them (7 out of 41) waited 
for six months or longer.
Overview of the grounded theory
According to our grounded theory (Fig. 1), prior to visit-
ing SSPs PWID were in high need of free sterile syringes 
due to the high cost and limited access of syringes out-
side of SSPs. Still, PWID hesitated to visit SSPs because 
of stigma. They feared persecution by law enforcement, 
and judgment and ostracism by friends, family, health-
care providers and by the general public. We categorized 
this fear as anticipated stigma. PWID also hesitated 
to enroll in the SSPs because of shame and feelings of 
unworthiness related to their drug use; we categorized 
these experiences as internalized stigma. According to 
our emergent grounded theory, anticipated and internal-
ized stigmas were mitigated or amplified by individual- 
(gender, child custody, social status), network- (family, 
peer support) and organizational-level (low threshold-
SSP services) factors.
We start illustrating the theory by describing two 
cases—one participant who waited for a long time after 
hearing about the SSP, and another who started visiting 
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Fig. 1 Model of syringe service program initiation by people who inject drugs (following the Intersectional Risk Environment Framework)
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cases provide real-life illustrations of how network, 
organizational and individual-level factors influenced 
our participants’ decision to start visiting SSP (Box  1). 
Case descriptions are followed by detailed and struc-
tured descriptions of the findings elucidating the main 
categories of the grounded theory and the relationships 
between them.
Box 1. Deciding to visit SSP—short and long lag (delay 
in the first visit to SSP)
Case # 1 (short lag): Todd (pseudonym) is 37  years 
old, has young children and lives in county B. Prior to 
enrolling in the SSP, Todd used to buy syringes from 
pharmacies and on the black market. He reused his 
own syringes after cleaning them, and did not practice 
receptive syringe sharing. He learned about the pro-
gram via his social network—a friend told him about 
it. Unfamiliar with SSPs, he initially hesitated to visit 
the program for about two weeks because of anticipa-
tion of structural stigma—he feared that police may 
arrest him for drug possession or under some other 
pretext. He was also worried about losing custody of 
his children if SSP staff reported him to child protec-
tion service:
I’m like oh man, … they’re going to arrest you when you 
go up there [to SSP] … They’re going to get you for a PI 
or public intoxication, I mean DUI or try to hit you 
with possession or something. Because I had a nephew 
get a county year in jail for having a syringe… And, so 
I thought, no man, you know you all crazy to do it. […] 
I thought maybe – I have kids, right, so I thought well, 
I’ll come up [to SSP], I go up and sign my name…, [then 
SSP staff] want [to notify] social workers, you know 
what I mean, with kids and whatnot.
However, his social network members who had vis-
ited the SSP helped him overcome his concerns when 
he talked to them and found out no one had been 
arrested:
Interviewer (I): So, after you first heard about it, about 
how long did it take you to decide and go to the pro-
gram?
Participant (P): … about two weeks, first week I was a 
little bit hesitant about it, … talked to somebody that’d 
been here and went [to SSP]. And seen that they wasn’t 
in jail, and I thought alright, I’ll go.
Case #2 (long lag): Nancy (pseudonym) is 41 years old, 
a mother of two children (one of them young), has two 
brothers who also inject drugs, and lives in county A. 
Nancy hesitated for six months before deciding to visit 
the program. Prior to SSP enrollment, she too used to 
buy syringes on the black market, cleaning them with 
alcohol and bleach; she also reused her own syringes. 
To the best of her knowledge, Nancy did not inject 
with borrowed syringes before attending the local SSP 
because she was concerned about her health. Nancy 
had no prior awareness of SSPs and heard about the 
program in her county via her social network: a close 
friend who was an SSP client told her about the pro-
gram. Internalized and anticipated stigma were the 
main barriers delaying SSP enrollment. A long-time 
resident in her small rural county, Nancy was ashamed 
and embarrassed at the thought of potentially bump-
ing into an acquaintance there:
… this is a very small town. I’ve lived here my entire 
life. Just the fact of running into [people I know] – I just 
find it really embarrassing. I find it mortifying, really.
Nancy was also concerned about police seeing her 
visiting the program. She discussed the possibility of 
visiting the SSP with her friend and her boyfriend, 
who encouraged her to enroll to the program. Even-
tually her need for syringes, both for herself and her 
brothers, overcame her concerns about stigma, and 
motivated her to enroll. One day, six months after first 
hearing about the program, Nancy mustered the cour-
age to visit the program unaccompanied. After enroll-
ing in the SSP, Nancy encouraged her boyfriend to 
start attending too.
I: Okay. So then what kind of led you to the decision to 
come? You said it took you about six months, and you 
were talking to your friend.
P: The fact of having clean syringes – that was a very 
important thing. It was a lot safer that way.
I: So, who all did you talk about coming here with?
P: Well, she’s a really close friend of mine; and my boy-
friend at the time – my boyfriend – we talked about 
it. I came first. I just decided one day. I couldn’t make 
myself come, actually; and then one day I decided to 
try it, and I came without letting anybody know. I just 
came hoping for the best, that there wouldn’t be a lot of 
people. I didn’t know what to expect. I came, and then I 
told [my boyfriend] about it; and then he started com-
ing, too.
Healthcare environment—scarcity of syringes 
outside of SSP
Unmet need for free and sterile syringes1 was the main 
reason that PWID started visiting SSPs. Lack of access to 
syringes and their high cost outside of SSPs were main 
features of healthcare environment that drove high need 
1 Throughout the text we refer to syringes as a set of a syringe and needle.
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for sterile syringes among PWID. In the absence of sterile 
syringes, PWID engaged in risky injecting practices.
Prior to visiting the SSP, PWID in all counties had 
highly unreliable access to syringes because it was diffi-
cult to purchase them over the counter. Almost all par-
ticipants prior to enrolling in the SSP bought syringes 
on the black market from people who sell drugs or from 
people with diabetes. Black market syringes cost about 
$5 per syringe,q12 a price too high as mentioned by many 
participants. In addition, syringes bought on the black 
market might not be sterile:
P: You’d never know when you’d be able to get a new 
[syringe] or not. Some people you’d have to watch 
out, because they would try to sell you some; and 
they’d be used. […] the new ones – they’ve got an air 
pocket that you have to pop when they’re brand new. 
[…] It’s not on the used one.
 - a man from county A
Several participants mentioned buying syringes with-
out a prescription in pharmacies located in large cities 
outside of the study area. The cost of syringes in these 
pharmacies was much lower—$13 per 100—compared 
to the black  marketq2. However, PWID had to spend con-
siderable time driving to large cities to buy syringes from 
pharmacies, and urban pharmacies were not always a 
reliable source of syringes since pharmacists might have 
refused selling syringes at their discretion:
But like back in the day when you used to be able 
to buy them at Walmart…in Lexington. We had to 
drive … to Lexington to get a dollar and a half pack 
of rigs. […] But then we started coming and getting 
too many and they shut us down.
 - a woman from county E
Limited access to syringes led to risky injection prac-
tices—almost all participants reported reusing their own 
syringes and some participants reported engaging in 
receptive syringe sharing (i.e., using a syringe after some-
one else) prior to SSP enrollment. Reusing old syringes 
made the needles dull and burred, resulting in injured 
and scarred veins and soft tissue, also causing pain and 
discomfort. A man from county B described using a dull 
needle as “…sticking a railroad spike in my arm.”
Stigma and hesitation to visit SSP
As shown above, many participants in our sample 
had unmet demand for sterile inexpensive syringes. 
Nevertheless, about half of our participants reported 
postponing their first visit to SSP after learning about 
the program for a month or longer. All participants who 
delayed their visit to the SSP and some participants who 
started visiting the SSP relatively soon after hearing about 
it expressed reluctance to visit the program because they 
anticipated various forms of drug-related stigma. Here, 
we describe the most common forms of stigma that 
caused concern and delayed SSP visits: a) fear of per-
secution by law enforcement and other legal repercus-
sions; b) anticipation of stigma enacted by public, family 
and friends if their drug use were disclosed; and c) fear 
of possible mistreatment by SSP providers. Importantly, 
participants’ accounts also elucidated how individual and 
environmental factors mitigated or amplified the fear of 
stigma as a barrier to visiting SSP. We describe the vari-
ous types of anticipated stigma and factors modifying its 
effect in the subsections below.
Fear of law enforcement
PWID feared that visiting an SSP would provide evidence 
of illicit drug use, and so were reluctant to start visiting 
SSPs. Many participants were afraid that the SSP was a 
police setup to identify and target PWID. Some partici-
pants initially believed that SSP staff collaborated with 
police and shared information about clients. One par-
ticipant refused to visit the SSP when she heard about it, 
since she believed police would arrest PWID visiting the 
program.
They was a friend of mine that told me that this 
program was going on; and I said, my God. I said 
every one of us in this town is going to go to jail. […] 
I thought it was just a joke really; and [my friend 
is] like, no, they give [syringes], and then you take 
them back every time you – I said you’ve lost your 
mind, because when you go down there and do there, 
there’s the law going to be sitting there, take your ass 
to jail. I said well, when you go to jail, don’t say I 
didn’t tell you so.
 - a woman from county C
This fear of police was based on past persecution of 
PWID by law enforcement, as reported by many par-
ticipants. While most participants’ accounts of stigma 
enacted by law enforcement focused on police officers 
stopping, searching, arresting and confiscating syringes 
from SSP clients, some participants also recalled episodes 
of arrests and imprisonment for paraphernalia charges 
that occurred prior to the SSP’s opening. Persecution 
of PWID by police was not a mere act of enforcing the 
law, but also manifestation of stigma against PWID since 
many police officials shared negative attitudes toward 
PWID. A participant recalled the local sheriff ’s political 
2 Here and below we use numbered superscripts to reference additional 
quotes compiled in the Additional file 1.
Page 8 of 15Ibragimov et al. Harm Reduct J           (2021) 18:68 
platform based on “cleaning up” the county by incarcerat-
ing people who use drugs:
P: Well, during his campaign he kept hollering that 
he was going to “clean up” [our] County, he was going 
to put all the drug addicts in jail, he was going to put 
all the drug dealers in jail, and he just looks down on 
us. That we’re nothing, more or less...
 - a woman from county C
Fear of public stigma
Anticipation of public stigma was a common reason for 
delaying SSP enrollment. PWID feared that their fam-
ily members, friends, employers and other members of 
the general public would find out about their drug use 
if they visited SSP. According to participants, public 
stigma toward PWID was prevalent in the study coun-
ties. PWID were perceived as people of lower value who 
“do not matter,” who engaged in crime and damaged 
the local communities.q3 In this setting, PWID wanted 
to hide their drug use, even from their family members 
and friends. They worried that visiting the SSP might 
inadvertently reveal their drug use and subject them to 
ostracism and ridicule by kin and kith. Some participants 
mentioned visiting SSPs in another county to avoid being 
seen by familiar people. In some cases, PWID concealed 
their drug use from family members to spare them from 
embarrassment and stigma by association. A participant 
mentioned that while her adult children might know 
she used drugs, she did not want them to be confronted 
about it by others:
[…] like I said, my children were of age, I didn’t want 
them to find out [about my drug use]. In the same 
talking, my daughter’s a social worker she prob-
ably knows more than I think she knows. She’ll be 
a [healthcare professional] coming this spring when 
she graduates this year… So, she probably knows a 
whole lot more than what I think. But I just didn’t 
want them exposed to that. And I didn’t want them 
to have people coming up and say, hey, we’ve seen 
your mom with at the needle exchange. So that’s the 
only [concern I had about visiting SSP].
 - a woman from county B
Living in small tight-knit communities where many 
people know one another and rumors spread fast ampli-
fied fear of public stigma. In some cases, PWID were 
reluctant to visit the SSP since their friends or acquaint-
ances worked at county health centers where SSPs were 
located. PWID feared that these people might tell their 
families and friends about their SSP use:
Some people don’t want nobody seeing you come in 
to get [syringes], some people’s parents or kinfolks 
work [in the Health Center], or lives next to a person 
that lives here and they don’t want them to know.
 - a man from county C
Anticipation of public stigma was seemingly com-
pounded by internalized stigma, as some PWID avoided 
SSPs because it reminded them of their perceived failure 
and moral weakness.q4, q5 A participant was embarrassed 
to visit SSP because she was ashamed of her drug use:
I: Were you worried about anything about trying this 
program out for the first time?
P: Just ashamed and didn’t want no one to know me, 
which no none here knows me much anyway, but that’s 
not the point. I just - there’s always going to be shame. 
I’m 48 years old. I’m a grandma. I didn’t get it over 
this to kick it in the butt - kick it to the curb, you know. 
And I’m trying my best to do so. The day I don’t have 
to come here and get a pack of needles I’ll be so happy.
 - a woman from county D
PWID might also delay visiting SSPs due to anticipation 
of stigma by SSP staff. As indicated above, living in a small 
community increased chances of PWID seeing someone 
familiar working at a SSP or health center. Some partici-
pants believed that SSP staff would share clients’ informa-
tion with law enforcement or treat clients with prejudice.q6 
Fear of stigma by SSP staff might be based on negative expe-
riences of PWID who were stigmatized by other healthcare 
providers. A participant recalled a disparaging remark from 
a local clinic staff:
[Healthcare staff] treat you like you’re nothing. Like 
you’re trash. … You look a certain way, whether you’re 
a user or not, you’re being treated as one. This area is 
real bad for it. I know when I had MRSA, I had a prob-
lem with one of the staff [who] made a comment to me 
that, "You’re nothing more than an old dopehead drug 
user, and I don’t even know why we’re fooling with you."
 - a woman from county D
Distrusting healthcare systems, some participants simply 
did not find the idea of an SSP credible initially. One of the 
participants who delayed joining SSP did so due to his dis-
belief in the idea of SSP:
I: What did you think about the program when you 
first heard about it? Or how did you feel about the pro-
gram?
P: I was sketchy about it at first, until I started actu-
ally going…. I just thought it was too good to be true or 
something. I don’t know. If something sounds good, it’s 
usually not a good thing, you know?
 - a man from county A
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Factors modifying stigma as a barrier to first visit
While analyzing stigma as a reason for the first visit to 
SSP, we identified several categories that amplified or 
mitigated the level of anticipated stigma or helped the 
participants to overcome strong anticipated stigma. 
These factors, including individual characteristics as 
well as factors belonging to social (PWID networks) and 
healthcare (SSPs) domains, are discussed below.
Individual‑level factors modifying anticipated stigma
The data suggest that gender is an important individ-
ual-level factor modifying the effect of stigma on delay-
ing the first visit to the program. Notably, participants’ 
gender may both amplify and mitigate stigma as a bar-
rier. SSPs were located in county health centers, and sev-
eral participants mentioned that they knew it as a place 
where women, including women with children, were 
regular visitors. Some women appeared to be more com-
fortable visiting these SSPs than men, as they found it 
easier to conceal their visit to an SSP as a visit for other 
 purposesq7:
I: What concerns did you have about coming to the 
program?
P: I didn’t have any. I just don’t want people to know 
what I do. I make up a story about something else 
that I do [in the county health center], but I just 
don’t want anybody to know.
I:  Do you mean you tell them you’re at the health 
department for something else?
P: Yeah.
 - a woman from county C
The role of gender was complex, however, and data 
also suggest that women, in particular mothers, might be 
more vulnerable to stigma, because society expects them 
to care for children and drug use was seen as not compat-
ible with motherhood:
I: Do you think there are any particular kinds of peo-
ple like women or younger people who might be less 
likely to come to the program?
P: Yes, mothers, young mothers or mothers in gen-
eral, who just don’t want people to look down upon 
them because they’re a mother or look down upon 
their kids somehow you know what I’m saying. They 
just don’t want people to think bad of them, like, I 
don’t have [to be seen as] a bad mom because I use.
 - a man from county E
PWID with young children were also susceptible 
to structural stigma, since disclosure of drug use sta-
tus might jeopardize their child custody.q8, q9 Notably, 
not only women, but also several men in our sample 
expressed concerns about losing child custody or expos-
ing children to stigma by association:
P: My kid ain’t never seen nothing, she never see 
nothing. I don’t even [use drugs] when I’m at the 
house. I always do it when I’m gone.
I: Where you worried that your daughter would 
know that you came [to SSP]?
P: Well, just maybe, maybe grown people would 
get the information [about my drug use], you know 
what I’m saying. Maybe cause me some problems … 
Maybe [they will] call social [child protection] ser-
vices or something … You got to worry about stuff 
like that, especially round this town.
 – a man from county B
Disclosure of drug use status might result in loss of 
social status or damage to personal relationships of 
PWID. Higher social status (including having higher 
income, being employed, older age or high status in 
family hierarchy) thus is a factor increasing individual’s 
susceptibility to higher internalized stigma and fear of 
anticipated sigma. Participants mentioned that some cat-
egories of professionals whose careers depended on their 
reputation might be at higher risk of losing their job if 
someone saw them at SSP:
A lot of people with, you know, jobs – like certain 
kind of jobs don’t come to the program because, you 
know, if the wrong person’s seen them at the pro-
gram, then they’re more likely to get fired…
I: What kinds of jobs would you say?
P: Like [a registered nurse]. Say like any kind of pub-
lic official definitely ain’t going to come in. Just pro-
fessions like that. I mean, they’re – that’s for sure not 
going to happen, you know.
 – a man from county B
Social domain—network‑level factors modifying anticipated 
stigma
While PWID might hesitate to visit SSPs lest their social 
network members learned about their drug use, as shown 
above, PWID networks also facilitated SSP enrollment 
by advertising SSP services and addressing misconcep-
tions about the program. Members of PWID social and 
drug using networks played a significant role in reduc-
ing anticipated stigma among their peers and encour-
aging enrollment to SSP. Learning about the SSP from 
people they knew was a reassurance for PWID who were 
hesitant, especially if the person sharing the information 
about the SSP has previously attended the program.q10, 
q11 Many participants in our sample were accompanied 
during their first visit by their family members, part-
ners or other trusted peers who already started visiting 
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the program.q12 Some PWID hesitant to visit SSP asked 
their peers or non-PWID friends or family members to 
visit SSP to check if it is a safe and legitimate service. This 
happened particularly often when SSPs had just opened 
and their reputation among PWID had not been estab-
lished yet:
I said you go on and sign up for me and get your lit-
tle things. What you want to do, you go over there 
and get and I said, let’s see if you make it back down 
here or not. I thought it was just a joke really […] I 
sat down there [near SSP] and never moved from it.
 - a woman from county C
Gradually, SSPs’ reputation of safe and legitimate ser-
vices grew among PWID networks over time, as more 
PWID spread positive information about the programs. 
This was self-perpetuating: many participants also men-
tioned that after they started visiting SSP, they encour-
aged their friends to come to the program. Some of them 
gave out new syringes from SSP to reassure their hesitant 
peers:
I: So, since you’ve started coming here, have you 
encouraged other people to come?
P: Oh yeah, word of mouth is the best thing you’ve 
got.
I: What do you usually tell them?
P: Tell them that -- you know, I’ll give them a couple 
[of new syringes] and switch them if they’ve got some 
old ones and stuff. Look, just walk down the street. 
They aren’t going to bite you, they won’t hit you, you 
know, I’ve been in [SSP]. They aren’t going to arrest 
you. So why not? You haven’t got nothing to lose 
really.
 - a man from county E
Healthcare domain—SSPs countering anticipated 
stigma The provision of low threshold, anonymous 
and PWID-friendly services by SSPs was a key for their 
positive reputation among PWID, eventually helping to 
assuage their fears and concerns related to visiting SSP. 
All SSPs in our study took precautions to protect clients’ 
privacy and confidentiality, lest stigma prevents them 
from enrolling to the program.q13 For example, SSPs’ loca-
tion in county health centers allowed their clients to blend 
in with other health center patients. Importantly, all SSPs 
issued program IDs to their clients to protect them from 
arrest or from police confiscation of their syringes. This 
was a key motivation for many PWID to start attending 
an SSP:
I: So then what kind of things would you say to these 
people to kind of talk them into maybe giving [SSP] 
a try?
P: I’m thinking I ended up convincing like maybe one 
or two. The card they give you, you know, showing 
that you’re part of the program. So, if you get pulled 
over by the cops and stuff, as long as you don’t have, 
you know, the paraphernalia associated with it, you 
know, you can, you know, skate by with it. You know, 
that card was beneficial so they knew that if they 
got caught with rigs in the car, you know, traveling 
back home or something, you know, they’re good. 
You know, they don’t have to worry about nothing. I 
think that was the key to, you know, getting a couple 
of my friends to start coming here.
 – a man from county A
Personal awareness of or experience with SSPs also 
helped participants to avoid or overcome hesitation to 
visit the program. Participants who were aware of SSPs 
prior to their first visit, especially those who visited SSPs 
in other locations, knew about the program purpose 
and confidentiality protection measures. These partici-
pants anticipated much less stigma and tended to visit 
SSPs sooner.q14 We found no evidence that variations in 
SSP operations (e.g., hours) were related to variations in 
enrollment across programs.
Negative cases
Contrary to the numerous accounts of anticipated and 
internalized stigma, there were several participants who 
did not internalize stigma related to drug use (negative 
cases). Across the study counties, several participants 
were not worried about others finding out about their 
drug use and visited a SSP soon after learning about it.
I: So, did you have any concerns about trying the 
program out? Anything that made you a little bit 
hesitant about coming?
P: No. At least get it over with, put this on that. I 
said I don’t give a damn who knows it. You can put 
it in the paper for all I care. That’s just the way I am.
 - a woman from county D
Discussion
To effectively address epidemics of drug-related 
harms, SSPs opening in areas such as rural Kentucky 
with limited access to sterile syringes and high preva-
lence of IDU and HCV need to reach a high propor-
tion of PWID. Drawing on empirical data and IREF, 
we developed a grounded theory conceptualizing how 
the interplay of PWID social locations (individual-level 
characteristics) and various domains of the rural inter-
sectional risk environment produces and influences 
stigma as a major barrier to SSP initiation. The role of 
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stigma as a barrier to SSPs and other services target-
ing PWID in the USA, including rural Appalachia, is 
well documented [10, 17, 27, 54]. For example, 19% of 
PWID surveyed in Appalachian Kentucky cited fear of 
stigma as a barrier to SSP enrollment [10]. The most 
prominent manifestation of anticipated stigma in our 
study was fear of police persecution, a theme recur-
ring in other publications on rural Appalachia [20, 55]. 
Enforcement of laws criminalizing possession of drugs 
and injecting equipment is a well-documented struc-
tural determinant of health. Past research in Appa-
lachia and elsewhere has found that PWID who fear 
arrest tend to avoid SSPs and other HIV prevention 
services, or are reluctant to carry injecting equipment 
[20, 22–24]. Furthermore, fear of arrest, having been 
arrested, police confiscation of syringes, not carrying or 
buying syringes and rushing injections for fear of police 
are linked to higher rates of HIV [22, 23].
Our findings corroborate this literature, showing how 
various manifestations of stigma—anticipated, internal-
ized, enacted and structural—make PWID reluctant to 
visit SSPs despite high unmet need for sterile injection 
equipment. The most important and novel contribution 
of our grounded theory to the stigma literature, though, 
is conceptualization of meso-level risk environment 
domains and individual’s social locations as factors that 
amplify or mitigate the role of stigma as a barrier to SSP 
services in rural settings.
Our grounded theory suggests that social networks are 
significant features of PWID’s meso-level social domain, 
influencing the impact of stigma as a barrier to SSP ser-
vices. Dense family and broader social networks, a main-
stay of rural Appalachians’ social support system [52, 53, 
56], may play both negative and positive roles in promot-
ing enrollment in SSPs. Fearing loss of this support sys-
tem, PWID may decide against visiting the SSP, since it 
is hard to keep these visits private in small and tight-knit 
rural communities, and because SSP are run by county 
health center staff (the latter resulting from restrict-
ing SSP legislation in Kentucky, as discussed below). 
On the other hand, PWID’s peer networks may mitigate 
anticipated stigma by encouraging PWID to start visiting 
SSPs. In rural areas, PWID networks are also indispen-
sable in informing their peers about the programs, since 
lack of awareness about SSP is one of the major barriers 
to enrollment [10]. The positive role of PWID peer net-
works in promoting SSP use is documented in the litera-
ture, including a study among PWID in rural Kentucky 
[26]. Globally, SSPs often capitalize on PWID networks 
by actively involving PWID in service provision, includ-
ing outreach work and secondary exchange [57, 58].
Importantly, IDU social network members may encour-
age PWID to visit SSP if only these services are worth 
visiting. This analysis found that the positive reputation 
of SSPs among PWID networks was built and main-
tained by evidence-based implementation of services by 
staff at the local SSPs (meso-level healthcare domain). 
As attested by our participants, SSPs operating in these 
counties attracted PWID by meeting their needs in a low 
threshold, confidential and friendly manner. Specifically, 
the programs offered free syringes and other injecting 
equipment (both directly and via secondary exchange), 
provided services anonymously, protected clients’ privacy 
and treated them with dignity. SSPs also help to reduce 
the impact of structural stigma by issuing program IDs to 
protect their clients from police searches, syringe confis-
cation and arrest. These findings on the role of programs 
and social networks in reducing stigma and promoting 
access to services contribute to the growing acknowl-
edgement of meso-level in REF literature, [59] showing 
how these factors absorb the impact of negative forces 
such as stigma acting at other levels of environment.
Notably, we found no evidence of a relationship 
between SSP characteristics and enrollment delays. 
Characteristics of SSP service provision mentioned in 
the literature [26, 60], (e.g., hours of operation, syringe 
exchange rules, lack of mobile SSPs or range of available 
services other than sterile syringes) did not seem to fac-
tor into our participants’ decision to enroll to the SSP. 
Perhaps these characteristics were not as important for 
the first visit to the program as they might be for continu-
ous SSP attendance, or for other program outcomes such 
as client satisfaction or meeting their needs in services.
Similarly, our analysis did not identify factors pertain-
ing to other domains of the rural risk environment that 
might have affected delayed enrollment. For example, 
geographic remoteness, lack of public transportation and 
costly private transportation for impoverished residents 
are well-known impediments to accessing drug-related 
and other health care services in rural Appalachia, but 
were not mentioned here [24, 55, 61–64]. Most likely, 
these prominent features of the rural risk environment 
may affect continuous attendance of SSP rather than 
PWID’s decision to visit the program for the first time.
Our interviews did not elicit much information on 
the impact of legal environment on SSP enrollment. 
The state of Kentucky does not fully exempt SSP partici-
pants from drug paraphernalia charges, [65] which may 
raise additional concerns among PWID contemplating 
SSP enrollment. Kentucky’s SSP legal framework limits 
syringe distribution to health departments and requires 
approval of the new programs by local authorities, effec-
tively preventing SSP establishment or limiting its scope 
of operations in counties where municipal bodies disap-
prove of SSPs [66]. This legislation also prohibits commu-
nity-based organizations (CBOs) from operating SSPs, 
Page 12 of 15Ibragimov et al. Harm Reduct J           (2021) 18:68 
which may create additional barriers for engaging PWID. 
PWID, however, did not raise concerns relating to these 
issues. We did identify though several individual-level 
factors or, following IREF terminology, social locations, 
that may interact with stigma as a barrier to SSP initia-
tion. Gender is one such characteristic. While our sample 
had roughly the same number of men and women as par-
ents or custodians of underage children, women in the 
USA are more likely to have custody over children than 
men, [67, 68] and, in case of women who inject drugs, to 
have child custody-related concerns about visiting SSP. 
Literature also shows that women who inject drugs, in 
particular mothers, are subject to harsher judgment by 
the society as compared to men, and may be more likely 
to avoid visiting harm reduction services [69]. Impor-
tantly, the aforementioned survey among PWID in Appa-
lachian Kentucky found that men were more favorable 
toward SSPs being located in county health centers than 
women were, while women were more likely to prefer 
local health department staff as SSP service providers 
[10]. These findings suggest that while women are warier 
to visit services in publicly visible locations, they prefer 
service providers associated with serving women and 
children.
High social location, including employment or posi-
tion in a family hierarchy, may have shaped delays in 
first visits: people who were higher status may have 
been reluctant to attend the SSPs because of status loss, 
a component of stigma. As conceptualized by Link and 
Phelan, status loss, or “downward placement of a person 
in a status hierarchy” [70 p.371], becomes a source of dis-
crimination. Individuals with higher position in the social 
hierarchy may also fear not meeting societal expectations 
affixed to their status [71]. Consequently, for people of 
higher status disclosure of their participation in stigma-
tized services is associated with failing societal expecta-
tions and facing discrimination.
Strengths and limitations of our study can be analyzed 
via the prism of Maxwell’s [72] validity framework. We 
enhanced descriptive validity (i.e., accurately capturing 
the content of participants’ accounts) by audio-recording 
the interviews and transcribing them verbatim. Inter-
pretative validity (i.e., accurately conveying the mean-
ing of participants’ accounts) was strengthened by joint 
development of codebook and reconciliation of coding 
discrepancies by the study team members. The steps 
to improve theoretical validity (i.e., the extent to which 
the grounded theory accurately reflects the phenom-
ena of interest and the relationships between them) 
included having a relatively large and diverse sample of 
SSP clients; consulting theoretical frameworks widely 
used in research on PWID; refining grounded theory 
against findings across five counties (cases). However, the 
theoretical validity of our study may be undermined by 
not including PWID who never visited SSPs. Overall, our 
grounded theory has limited applicability to SSP in urban 
settings due to lower anti-PWID stigma and higher level 
of SSP clients’ anonymity (or lower public visibility) in 
urban areas.
Public health and research implications
As suggested by our grounded theory and related litera-
ture, the impact of stigma on expanding SSP enrollment 
and coverage may be reduced at meso-level by following 
best practices of SSP implementation, including those 
implemented by SSPs in our study. Based on our findings 
and global literature on SSP, we suggest a range of recom-
mendations for rural SSPs in Kentucky and beyond. As 
demonstrated by SSPs in our study, anticipated stigma by 
law enforcement may be addressed by program manage-
ment and staff early by engaging local law enforcement 
to protect the program participants from paraphernalia 
charges and other forms of police harassment. Specific 
protective measures include issuing program IDs, reduc-
ing patrolling of the areas surrounding SSPs, and anony-
mous service provision. Law enforcement officers may be 
sensitized to the needs of PWID and importance of harm 
reduction approaches, as demonstrated by available evi-
dence-based anti-stigma interventions [73].
Early involvement of PWID as opinion leaders and 
program ambassadors to spread news about SSP may be 
particularly effective in rural settings with dense social 
networks, because PWID in these areas tend to trust 
their friends and family members more than healthcare 
providers, and news is most efficiently spread via word of 
mouth. Institutionalizing the role of PWID in SSP service 
provision, such as formally enlisting them as volunteers 
or hiring them as paid workers, as well as removing poli-
cies prohibiting SSP implementation by local CBOs and 
grass-root groups representing PWID, may also help 
convince hesitant PWID to enroll to the program.
Friendly and non-judgmental treatment of PWID, 
low threshold enrollment practices (e.g., no require-
ments for picture ID, insurance, residency proof, 
mandatory HIV testing, etc.) and maintaining clients’ 
confidentiality will further boost the program’s reputa-
tion among PWID networks that can catalyze enroll-
ment, as shown by our study and elsewhere [74–76]. 
Further, the programs should prioritize coverage of 
PWID with children and other individuals highly sus-
ceptible to stigma and legal repercussions, perhaps by 
increasing awareness of SSP confidentiality protections 
and expanding secondary syringe exchange. Multi-
modal service provision, including satellite and second-
ary syringe exchange, pharmacy-based and mobile 
SSPs, and novel syringe sources such as syringe vending 
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machines, may help programs to reach PWID at vari-
ous stages of readiness to visit the program [10, 57, 
58, 77, 78]. These meso-level interventions need to be 
accompanied by macro-level reforms addressing struc-
tural stigma against PWID as captured by us and other 
studies in rural Appalachia [10, 20, 55]. These reforms 
should include decriminalization of drug possession 
and injecting equipment possession, removing any bur-
densome and unjustified requirements for establishing 
and operating SSPs and mandating non-prescription 
sales of syringes at pharmacies. More research is 
needed on how these meso- and macro-level changes 
affect the enrollment of PWID into rural SSPs as well as 
on other SSP implementation and program outcomes, 
such as continuous attendance, reaching all PWID who 
need SSP services and meeting their needs in services.
Conclusions
As rural counties in Kentucky expanded SSP services 
at an unprecedented rate, little was known about how 
stigma could affect the pace of PWID enrollment into 
the programs in rural areas with no prior history of SSP 
operation. We found, however, that the relationship of 
stigma to enrollment appeared to vary by features of 
the social and healthcare environments (e.g., PWUD 
networks, organization of SSP services) and individual 
characteristics of PWID (e.g., gender, child custody 
and social status). SSPs opening in locations with high 
stigma against PWID need to ensure low threshold and 
friendly service provision, protect their clients from 
police and mobilize PWID networks to promote rapid 
enrollment. Broader legal and policy reforms may be 
needed to lower barriers for SSP enrollment.
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